Advertisement
Advertisement

Potassium acetate

Generic Medicine Info
Indications and Dosage
Intravenous
Hypokalaemia
Adult: For prophylaxis and treatment: Dosage is individualised based on the patient's response, clinical condition, ECG, and serum potassium levels. Dose is administered as a diluted solution via slow IV infusion. Normal daily requirement of potassium: 40-80 mEq. Dosage and infusion rate recommendations may vary among countries and between individual products (refer to local or specific product guidelines).
Renal Impairment
Severe: Contraindicated.
Reconstitution
Dilute with compatible infusion solutions (e.g. NaCl 0.9%, lactated Ringer's inj). Recommendations on the concentration of infusion may vary depending on the patient's condition and between countries (refer to local guidelines).
Contraindications
Adrenal insufficiency, hyperkalaemia. Severe renal impairment.
Special Precautions
Patient with metabolic or respiratory alkalosis, CV disease (e.g. heart failure, cardiac arrhythmias, heart block), acid-base alterations, condition that may contribute to hyperkalaemia or altered serum potassium levels (e.g. heat cramps, severe tissue breakdown from trauma or burns). Avoid extravasation. Do not administer undiluted or via IV push. Mild to moderate renal impairment and severe hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Cardiac disorders: Cardiac arrhythmia, heart block.
General disorders and administration site conditions: Weakness.
Injury, poisoning and procedural complications: Inj site reactions (e.g. pain, phlebitis).
Nervous system disorders: Paralysis, paraesthesia.
Psychiatric disorders: Confusion.
Vascular disorders: Hypotension.
Potentially Fatal: Hyperkalaemia.
IV/Parenteral: C
Monitoring Parameters
Monitor electrolytes (e.g. serum potassium, bicarbonate, magnesium) and acid-base status. May repeat serum potassium level 2-4 hours after administration to assess adequate replacement. Conduct ECG monitoring. Monitor IV infusion site for extravasation.
Overdosage
Symptoms: Hyperkalaemia manifested as increased serum potassium concentration and changes in ECG; may lead to cardiac depression, arrhythmia, or arrest.

Management: Supportive and symptomatic treatment. Discontinue potassium acetate, potassium-sparing diuretics, and other potassium-containing medications or foods. Initiate appropriate corrective measures to lower elevated serum potassium and restore acid-base balance, if necessary. May administer glucose 10% solution containing 10-20 units of crystalline insulin/1,000 mL via IV. Administer IV sodium bicarbonate to correct acidosis; may repeat after 15-20 minutes if necessary. In case of cardiac arrhythmias, may give IV calcium gluconate 10% 10-50 mL over 1-5 minutes; conduct continuous ECG monitoring. Severe hyperkalaemia may require treatment with exchange resins, haemodialysis, or peritoneal dialysis.
Drug Interactions
May increase the adverse or toxic effects of digoxin. May increase the risk of hyperkalaemia with potassium-sparing diuretics (e.g. amiloride, spironolactone, triamterene), ACE inhibitors (e.g. captopril, enalapril), and potassium-containing salt substitutes.
Action
Description:
Mechanism of Action: Potassium acetate acts as an electrolyte replenisher. Potassium, the major cation of intracellular fluid, is essential for the maintenance of acid-base balance, normal renal function, carbohydrate metabolism, and gastric secretion. It also plays a vital role in the conduction of nerve impulses in the heart, brain, and skeletal muscle and in the contraction of cardiac, skeletal, and smooth muscles.
Pharmacokinetics:
Distribution: Distributed to cells via active transport from extracellular fluid. Enters breast milk.
Excretion: Mainly via urine; skin and faeces (small amounts).
Chemical Structure

Chemical Structure Image
Potassium acetate

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 517044, Potassium Acetate. https://pubchem.ncbi.nlm.nih.gov/compound/Potassium-Acetate. Accessed Sept. 29, 2025.

Storage
Store between 20-25°C.
MIMS Class
Electrolytes
ATC Classification
B05XA17 - potassium acetate ; Belongs to the class of electrolyte solutions used in I.V. solutions.
References
Brayfield A, Cadart C (eds). Potassium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/09/2025.

Potassium Acetate Injection, Solution, Concentrate (Hospira, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 03/09/2025.

Potassium Acetate. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 03/09/2025.

Potassium Acetate. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 03/09/2025.

Potassium Supplements. UpToDate Lexidrug, AHFS DI (Adult and Pediatric) Online. American Society of Health-System Pharmacists, Inc. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 16/09/2025.

Disclaimer: This information is independently developed by MIMS based on Potassium acetate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2025 MIMS. All rights reserved. Powered by MIMS.com
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement